Alpha 2.0
Login Register
» Authors » Rachel Scheckter

Rachel Scheckter

Explore the profile of Rachel Scheckter including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 599
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Pharmacology
Top 10 Co-Authors
Ariane van der Straten
Thesla Palanee-Phillips
Krishnaveni Reddy
Jeanna Piper
Jared M Baeten
Craig Hoesley
Sharon L Hillier
Katherine Bunge
Elizabeth R Brown
Craig W Hendrix
Published In
J Acquir Immune Defic Syndr
AIDS Behav
Lancet HIV
Breastfeed Med
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial
Noguchi L, Owor M, Mgodi N, Gati Mirembe B, Dadabhai S, Horne E, et al.
Lancet HIV . 2025 Feb; 12(3):e180-e190. PMID: 39954697
Background: In 2021, WHO recommended dapivirine vaginal rings (DVRs) for HIV prevention, but noted evidence gaps for breastfeeding populations. This trial aimed to describe safety profiles associated with DVRs and...
2.
Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037)
Ho K, Hoesley C, Anderson P, Fernandez-Romero J, Friedland B, Kelly C, et al.
J Acquir Immune Defic Syndr . 2025 Jan; 97(4):379-386. PMID: 39808074
Background: On demand, topical PrEP is desired by those preferring episodic, nonsystemic PrEP. PC-1005 gel (MIV-150, zinc, and carrageenan) exhibits in vitro antiviral HIV-1, human papillomavirus (HPV), and herpes simplex...
3.
Depression Among Pregnant and Breastfeeding Persons Participating in Two Randomized Trials of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis (PrEP) in Malawi, South Africa, Uganda, and Zimbabwe
Stoner M, Mathebula F, Sedze N, Seyama L, Mohuba R, Fabiano Z, et al.
AIDS Behav . 2024 Mar; 28(7):2264-2275. PMID: 38526641
Depression is associated with lower adherence to oral pre-exposure prophylaxis (PrEP) to prevent HIV, but data are not currently available on how depression may affect use of other HIV prevention...
4.
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States
Liu A, Gundacker H, Richardson B, Chen B, Hoesley C, van der Straten A, et al.
J Int AIDS Soc . 2024 Mar; 27(3):e26223. PMID: 38444118
Introduction: Tenofovir-based oral pre-exposure prophylaxis is currently approved for HIV prevention; however, adherence in women has been low. A vaginal gel containing tenofovir (TFV) demonstrated partial protection to HIV but...
5.
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014
Rungmaitree S, Aurpibul L, Best B, Li X, Warshaw M, Wan H, et al.
J Pediatric Infect Dis Soc . 2023 Oct; 12(12):602-609. PMID: 37815035
Background: IMPAACT 2014 study is a phase I/II, multicenter, open-label, nonrandomized study of doravirine (DOR) co-formulated with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) as fixed-dose combination (DOR FDC) in...
6.
Acceptability and Use of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) During Breastfeeding in South Africa, Malawi, Zimbabwe, and Uganda
Stoner M, Hawley I, Mathebula F, Horne E, Etima J, Kemigisha D, et al.
AIDS Behav . 2023 Jul; 27(12):4114-4123. PMID: 37432541
This study examines qualitative acceptability of the dapivirine vaginal ring (DVR) and oral daily pre-exposure prophylaxis (PrEP) among breastfeeding persons participating in Microbicide Trials Network 043/B-PROTECTED, a phase 3B safety...
7.
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014
Melvin A, Yee K, Gray K, Yedla M, Wan H, Tobin N, et al.
J Acquir Immune Defic Syndr . 2022 Oct; 92(2):153-161. PMID: 36215957
Background: We studied the pharmacokinetics (PK) and safety of 100-mg doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate fixed-dose combination (100/300/300 mg DOR FDC) treatment in adolescents with HIV-1. Methods: Adolescents ages 12...
8.
Integrating Gender-Based Violence Screening and Support into the Research Clinic Setting: Experiences from an HIV Prevention Open-Label Extension Trial in Sub-Saharan Africa
Garcia M, Roberts S, Mayo A, Scheckter R, Mansoor L, Palanee-Phillips T, et al.
AIDS Behav . 2022 Sep; 27(4):1277-1286. PMID: 36178556
HIV and gender-based violence (GBV) are syndemic in sub-Saharan Africa and provision of support for participants who disclose GBV constitutes part of comprehensive care. Consequently, a process was undertaken to...
9.
Acceptability of PC-1005 Gel Administered Rectally to HIV-1 Seronegative Adults at Three Different Volume Levels (MTN-037)
Bauermeister J, Tingler R, Ho K, Scheckter R, McClure T, Davis J, et al.
AIDS Educ Prev . 2022 Aug; 34(4):257-271. PMID: 35994578
Multipurpose prevention technologies (MPT) have been increasingly researched for their dual-purpose preventative properties against HIV and other STIs. The acceptability of PC-1005, a topical MPT candidate, was explored among men...
10.
Women's experience receiving drug feedback and adherence counseling in MTN-025/HOPE - an HIV Prevention open-label trial of the Dapivirine Vaginal Ring
Katz A, Balan I, Reddy K, Etima J, Weber K, Tauya T, et al.
AIDS Behav . 2022 May; 26(11):3607-3619. PMID: 35536519
In the Phase IIIB MTN-025/HOPE open label extension trial, participants were offered the dapivirine vaginal ring as HIV prophylaxis, and those who accepted the ring received semi real-time individual adherence...